Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors.
Tsimberidou A.M., Beer P., Bendall J., Dow J., King J., McElwaine-Johnn H. and Wistuba I.I.
Abstract CT151. American Association for Cancer Research Virtual Annual Meeting I; April 27-28 2020.
Press Releases
- Karus Therapeutics Announces New Data from Phase I Cancer Trial at AACR 27 April 2020
- Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH 4 December 2019
- Karus Therapeutics Appoints Dr Stephen Shuttleworth as Chairman of Scientific Advisory Board 17 September 2019
- Karus Therapeutics Strengthens Clinical Leadership Team with Appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer 17 July 2019
- 2018 Operational Update 31 December 2018
Events
In The News
- Karus Therapeutics features in Biology Impacting Lives programme 11 October 2019
- Karus Therapeutics features in BioCentury Innovations 4 November 2016
- Karus Therapeutics features in SciBX 15 May 2014
- Karus Therapeutics showcased in BVCA’s Britain’s Hot Talents 2014/15 25 February 2014
- Karus Therapeutics interviewed by Pharma Television 17 July 2013
Publications & Abstracts
Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma.
Nastoupil L.J., Neelapu S.S., Davis E., Samaniego F., Fowler N.H., Westin J.R., Lee H.J., Wang M., Hagemeister F.B., Cecil A.R.L., Dow J., McHale D., Silva F., Ward P., Yavari A., Shuttleworth S.J.; and Beer P.
Abstract 4099. 61st American Society of Hematology Annual Meeting and Exposition; December 7-10 2019; Orlando, Florida (FL), USACompensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy
David Gyori, Ee Lyn Lim, Francis M. Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen J. Shuttleworth, Klaus Okkenhaug, Len R. Stephens, Phillip T. Hawkins
JCI Insight 2018, 3(11), e120631
Created by Instinctif Partners